Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Biotime Inc (BTX) AMEX

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 341,190
  • Shares Outstanding, K 103,390
  • Annual Sales, $ 7,040 K
  • Annual Income, $ -46,990 K
  • 36-Month Beta 1.70
  • Price/Sales 48.49
  • Price/Book 2.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.07 +4.89%
on 11/30/16
3.70 -12.97%
on 11/22/16
+0.07 (+2.22%)
since 11/08/16
3-Month
2.80 +15.00%
on 11/04/16
4.01 -19.70%
on 09/26/16
-0.27 (-7.74%)
since 09/08/16
52-Week
2.02 +59.41%
on 02/08/16
4.51 -28.60%
on 12/30/15
-0.43 (-11.78%)
since 12/08/15

Most Recent Stories

More News
Increased Earnings Estimates Seen for BioTime (BTX): Can It Move Higher?

BioTime (BTX) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

Why BioTime (BTX) Stock Might be a Great Pick

BioTime (BTX) is seeing solid earnings estimate revision and is well-positioned from a Zacks Industry Rank perspective.

BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress

--Initial 3-D Imaging data from Renevia(R) trial run-in patients suggest volumetric improvements are sustained at least 12 months

Data From BioTime's Renevia Pivotal Trial in HIV-Associated Facial Liopatrophy to be Presented at the 14th Annual IFATS Meeting on November 17

BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that an abstract evaluating Renevia(R) in 'run-in'...

BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that the company has appointed Jim Knight as Senior...

BioTime, Inc. to Announce Third Quarter Results on November 3, 2016

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that it will release third quarter financial and operating...

First Patient Cohort Data From BioTime's OpRegen(R) Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016

--- Retinal imaging suggests presence and survival of the transplanted cells in the subretinal space for up to one year -

LifeMap Solutions Joins Medidata AppConnect Partner Program to Drive mHealth Innovation

LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX), today announced a partnership with Medidata (NASDAQ: MDSO), the leading provider of cloud-based solutions...

BioTime to Present at the BIO Investor Forum

BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, will...

BioTime (BTX) Shows Strength: Stock Adds 5.9% in Session

BioTime, Inc. (BTX) moved big last session, as the company saw its shares rise almost 6%.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More

Business Summary

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body....

See More

Support & Resistance

2nd Resistance Point 3.28
1st Resistance Point 3.25
Last Price 3.24
1st Support Level 3.18
2nd Support Level 3.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.